resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference
13 Maio 2019 - 9:00AM
resTORbio, Inc. (Nasdaq: TORC) today announced that it will present
additional results from the Phase 2b trial evaluating RTB101
(dactolisib), an oral, selective, and potent inhibitor of target of
rapamycin complex 1 (TORC1), in an oral presentation entitled “Oral
TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the
Incidence of Respiratory Tract Infections (RTIs) in Elderly
Subjects with Asthma” during the American Thoracic Society (ATS)
International Conference in Dallas, Texas from May 17-22, 2019
(abstract #A2623).
“RTIs are one of the most common triggers of asthma
exacerbations and are caused by many different kinds of viruses,
most of which lack current treatments,” said Joan Mannick, MD,
Chief Medical Officer of resTORbio. “Preventing RTIs is of
particular importance in asthmatics who are age 65 years and older.
Asthma exacerbations are associated with a 5-fold increased risk of
overall mortality in older as compared to younger adults with
asthma. We look forward to presenting findings from our Phase 2b
clinical trial in which the small molecule TORC1 inhibitor RTB101
was observed to decrease the incidence of RTIs caused by multiple
different viruses in asthma patients age 65 and older.”
Following are details for the presentation:
Session: |
B15 – Immunotherapy for Lung Disease |
|
|
Presentation Title: |
A2623 - Oral TORC1 Inhibitor Dactolisib Enhances
Immune Function and Reduces the Incidence of Respiratory Tract
Infections in Elderly Subjects with Asthma |
|
|
Presenter: |
Joan Mannick, MD, Co-Founder, Chief Medical Officer,
Board of Directors, resTORbio |
|
|
Date/Time: |
May 20, 2019, 9:45 AM - 10:00 AM CDT |
|
|
Room: |
Room C146 (Level 1), KBHCCD |
About Respiratory Tract Infections in the
ElderlyAs part of the aging process, the immune system
weakens and becomes less effective at detecting and fighting
infections such as RTIs. As a result, RTIs are more likely to be of
greater severity, prolonged duration, and are more likely to be
associated with medical complications in people age 65 years and
older as compared to younger adults. In the U.S., RTIs are the
fourth leading cause of hospitalization and seventh leading cause
of death in people aged 65 and older. Given that RTIs are caused by
many different types of viruses, most of which lack effective
therapies, there remains a significant unmet medical need for an
immunotherapy that enhances the ability of the immune system to
fight multiple viruses to reduce illness associated with RTIs in
the elderly.
About RTB101RTB101 is an oral, selective, and
potent TORC1 inhibitor product candidate. TORC1 inhibition
has been shown to be of therapeutic benefit in multiple
aging-related conditions in preclinical species including
immunosenescence (aging-related decline in immune function). In two
Phase 2 clinical trials enrolling over 900 elderly people, RTB101
was observed to improve immune function by upregulation of
antiviral gene expression and to reduce the incidence of RTIs.
About resTORbioresTORbio, Inc. is a
clinical-stage biopharmaceutical company developing innovative
medicines that target the biology of aging to prevent or treat
aging-related diseases. resTORbio’s lead program selectively
inhibits TORC1, an evolutionarily conserved pathway that
contributes to the decline in function of multiple organ systems,
including the immune, cardiovascular and central nervous systems.
Learn more about resTORbio, Inc. at www.resTORbio.com.
Forward Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Investors are cautioned that statements in this press
release which are not strictly historical statements, including,
without limitation, express or implied statements or guidance
regarding our future plans to develop RTB101 alone or in
combination with rapalogs, such as everolimus or sirolimus,
including the therapeutic potential and clinical benefits thereof
and the potential patient populations that may be addressed by our
product candidates, our ongoing and future clinical trials for
RTB101, including the timing of the initiation and anticipated
results of these trials, the intended regulatory path for our
product candidates and interactions with regulatory authorities,
and our ability to replicate results achieved in our clinical
trials in any future trials, constitute forward-looking statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” “anticipate,” or “could” and similar
expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation, risks associated with: our planned Phase 3 clinical
trials in RTIs and/or development of RTB101, either alone or in
combination with a rapalog, such as everolimus or sirolimus; our
ability to successfully demonstrate the efficacy and safety of our
lead product candidate; the clinical results for our lead product
candidate which may not support further development of additional
indications; uncertainties related to the results of our clinical
trials predictive of future results in connection with future
trials, including our Phase 3 clinical trials; the timing and
outcome of our planned interactions with regulatory authorities;
and obtaining, maintaining and protecting our intellectual
property; as well as those risks more fully discussed in the
section entitled “Risk Factors” in the Annual Report on Form 10-K
filed by resTORbio, Inc. with the Securities and Exchange
Commission, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. In
addition, any forward-looking statements represent our views only
as of today and should not be relied upon as representing its views
as of any subsequent date. resTORbio explicitly disclaims any
obligation to update any forward-looking statements.
Investor Contact Michael SchaffzinStern
Investor Relations,
Inc.212-362-1200michael.schaffzin@sternir.com
Media ContactEllen MurphyBiosector
2212-849-9496Ellen.Murphy@syneoshealth.com
resTORbio (NASDAQ:TORC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
resTORbio (NASDAQ:TORC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024